Key takeaways:
- Individuals with weight problems and prediabetes assigned tirzepatide have been extra more likely to have sustained weight reduction than these assigned placebo.
- Most individuals on tirzepatide sustained weight reduction by way of 176 weeks.
CHICAGO — In adults with weight problems and prediabetes, weight reduction achieved with tirzepatide was sustained at greater than 3 years, in keeping with new information from the SURMOUNT-1 research.
As Healio beforehand reported, in the primary SURMOUNT-1 research, almost all members assigned tirzepatide (Zepbound, Eli Lilly) skilled a minimum of 5% weight reduction over 72 weeks in contrast with placebo — greater than half on the very best 15 mg dose had a minimum of 20% weight reduction. Healio | Endocrine In the present day Editorial Board Member Jamy D. Ard, MD, FTOS, professor of epidemiology and prevention and inside drugs and vice dean for medical analysis at Wake Forest College College of Drugs and quick previous president of The Weight problems Society, introduced a put up hoc evaluation of SURMOUNT-1 on the American Diabetes Affiliation Scientific Classes.
Information from the SURMOUNT-1 trial confirmed adults with weight problems and prediabetes maintained their weight reduction with continued tirzepatide remedy for greater than 3 years. Picture: Adobe Inventory
“We had good proof that continued use of tirzepatide was vital for upkeep of misplaced weight from the SURMOUNT-4 trial,” Ard informed Healio. “The prolonged therapy section of SURMOUNT-1 in these with prediabetes additionally confirmed that greater than 20% weight reduction could possibly be sustained at slightly over 3 years of therapy.”
Jamy D. Ard
For the put up hoc evaluation, Ard and colleagues analyzed members from SURMOUNT-1 who had weight problems and prediabetes at baseline and weight measurement out there at 176 weeks. The cohort included 143 members assigned tirzepatide 5 mg, 164 members assigned tirzepatide 10 mg, 151 members assigned tirzepatide 15 mg and 114 members assigned placebo.
At 176 weeks, weight reduction was as follows:
- 99% of these assigned tirzepatide misplaced a minimum of 5% of physique weight vs. 68% of the placebo group;
- 92% to 98% of the tirzepatide teams misplaced a minimum of 10% of physique weight vs. 40% of the placebo group;
- 70% to 93% of the tirzepatide teams misplaced a minimum of 15% of physique weight vs. 22% of the placebo group; and
- 48% to 80% of the tirzepatide teams misplaced a minimum of 20% of physique weight vs. 7% of the placebo group.
As well as, physique weight discount was sustained for longer within the tirzepatide teams in contrast with the placebo teams, the researchers discovered.
- For the load discount goal of a minimum of 5%, median time sustained was 167 weeks to 168 weeks for the tirzepatide teams vs. 164 weeks for the placebo group.
- For the goal of a minimum of 10% weight reduction, median time sustained was 160 weeks to 161 weeks for the tirzepatide teams vs. 128 weeks for the placebo group.
- For the goal of a minimum of 15% weight reduction, median time sustained was 141 weeks to 153 weeks for the tirzepatide teams vs. 65 weeks for the placebo group.
- For the goal of a minimum of 20% weight reduction, median time sustained was 129 weeks to 140 weeks for the tirzepatide teams vs. 65 weeks for the placebo group.
“Clinically, we see that individuals are more likely to reply early to therapy; this end result confirms that impression,” Ard informed Healio. “That therapy response is sustained whereas on therapy. The primary factor we in all probability didn’t totally recognize is that those that will are inclined to lose a minimum of 20% in the long run are inclined to cross that threshold round 36 weeks.”
The put up hoc evaluation “reaffirms the recommendation that continued therapy helps ongoing therapy response,” Ard mentioned. “Moreover, I’d say that if somebody wants to attain a minimum of 20% weight reduction, in the event that they haven’t reached that threshold by 9 months, it’s unlikely that this therapy alone will do it. The excellent news is that most individuals — 73% to 80% — on the ten mg to fifteen mg dose can get that impact.”
For extra data:
Jamy D. Ard, MD, FTOS, may be reached at jamy.ard@advocatehealth.org.
Sources/Disclosures
Collapse
Ard JD, et al. Summary 144-OR. Introduced at: American Diabetes Affiliation Scientific Classes; June 20-23, 2025; Chicago.
Disclosures:
The SURMOUNT-1 research was funded by Eli Lilly. Ard stories receiving analysis assist from Boehringer Ingelheim, Eli Lilly, Epitomee, Nestlé Well being Science, Regeneron and Weight Watchers Worldwide and consulting for Amgen, Amplifier Therapeutics, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Regeneron and WeightWatchers Worldwide.
